1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
IPCA Laboratories Limited

IPCA Laboratories Limited

1,903.50
INR
-15.40
(-0.80%)
54.21EPS
32.95P/E
431.55BMarket Cap
Nov 09Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
128.65
123.48
113.63
122.56
127.04
146.14
180.43
211.86
227.29
244.65
300.44
349.01
376.92
399.14
Basic EPS, GAAP
18.95
10.27
3.81
7.71
9.49
17.61
24
45.01
34.85
18.58
21.57
29.08
44.98
51.63
Free Cash Flow per Basic Share
5.65
-3.57
18.29
5.77
8.1
12.68
10.45
28.77
14.86
12.27
21.05
21.51
19.16
- -
Dividend per Share
2.62
1.46
0.61
0.01
0.61
0.61
4.82
4.01
4
4
2
4
2.07
- -
Book Value per Share
77.64
87.03
89.51
97.28
106.52
123.56
143.55
185.32
215.36
230.27
249.59
273.88
317.84
- -
Tangible Book Value per Share
74.46
83.03
85.25
93.22
101.35
114.69
135.68
178.98
207.24
222.49
240.4
265.87
310.06
- -
Basic Weighted Avg Shares
252
252
252
252
252
253
253
253
254
254
254
254
254
254
Sales/Revenue/Turnover
32,470
31,166
28,680
30,934
32,066
36,922
45,587
53,660
57,665
62,069
76,224
88,546
95,625
101,256
Operating Margin (%)
22.05
11.88
6.12
8.64
8.84
14.49
16.34
24.56
18.43
11.35
12.26
15.31
17.05
17.8
Depreciation Expense
1,031
1,796
1,633
1,730
1,777
1,824
2,105
2,092
2,324
2,616
3,572
3,978
4,181
4,289
Net Income, GAAP
4,782
2,592
962
1,945
2,394
4,448
6,063
11,400
8,841
4,713
5,474
7,377
11,411
13,098
Effective Tax Rate (%)
24.17
28.23
17.52
25.77
17.59
19.08
18.32
17.29
19.79
33.99
37.2
30.38
24.24
23.98
Profit Margin (%)
14.73
8.32
3.35
6.29
7.47
12.05
13.3
21.25
15.33
7.59
7.18
8.33
11.93
12.94
Working Capital
8,100
6,831
6,520
7,859
9,379
12,803
15,293
22,764
29,913
33,835
31,833
38,823
40,699
- -
LT Debt
2,940
4,987
4,843
3,517
2,340
1,409
1,160
174
4,067
6,689
6,203
5,941
1,960
- -
Total Equity
19,597
21,965
22,592
24,553
26,886
31,379
36,411
47,161
55,407
59,153
77,270
83,883
95,241
- -
Return on Invested Capital (%)
22.56
8.51
4.24
6.11
7.07
12.33
15.12
23.35
14.73
6.81
6.2
7.97
11.69
- -
Return on Capital (%)
20.9
9.19
3.56
6.68
7.98
13.36
16.06
25.12
15.61
7.18
7.95
7.92
11.51
- -
Return on Common Equity (%)
27.22
12.47
4.32
8.25
9.31
15.31
17.97
27.37
17.39
8.34
8.99
11.11
15.2
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
6,128
- -
LT Borrowings
- -
1,091
- -
LT Finance Leases
- -
869
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
254
254
254
Market Capitalization
359,981
406,231
431,551

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
63,769
- -
Cash, Cash Equivalents & STI
- -
11,956
- -
Accounts Receivable, Net
- -
20,143
- -
Inventories
- -
27,310
- -
Total Current Liabilities
- -
23,069
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
6,128
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.74%
15.4%
13.54%
Free Cash Flow
18.41%
-0.58%
-10.95%
Net Income, GAAP
37.18%
7.29%
54.69%
Sales/Revenue/Turnover
12.99%
12.42%
8%
Total Cash Common Dividend
- -
- -
-48.35%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
20,926
23,549
22,454
22,467
88,546
2026
23,089
25,565
23,925
23,885
95,625
2027
27,881
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
7.58
9.05
9.78
2.67
29.08
2026
9.19
11.14
12.86
11.79
44.98
2027
15.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
4
2026
- -
- -
- -
- -
2.07
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pranay Godha
Full Time Employees
23,467
Sector
Health technology
Industry
Pharmaceuticals: major
Address
125, Kandivli Industrial Estate Mumbai MH India 400067
IPO Date
Feb 23, 1994
Website
ipca.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ipca Laboratories Limited (IPCALAB.NS) manufactures and markets a broad portfolio of pharmaceutical products, including active pharmaceutical ingredients (APIs), generic formulations, and branded generics across therapeutic categories such as anti-malarials, cardiovasculars, anti-infectives, anti-diabetics, pain management, anti-hypertensives, neuropsychiatry, gastro-intestinals, and vitamins and minerals; it also produces drug intermediates and provides contract research and manufacturing services (CRAMS). The company operates manufacturing facilities in India and exports to over 100 countries, targeting both regulated markets like the US and Europe as well as emerging markets in Africa, Asia, and Latin America. Founded in 1949 and headquartered in Mumbai, India, Ipca maintains subsidiaries including Ipca Pharma Nigeria Ltd and facilities approved by USFDA, EDQM, WHO, and other global regulators. In recent developments, Ipca launched new generic products including Sitagliptin Phosphate tablets for the US market in 2024 and expanded its anti-malarial portfolio with Artemisinin-based combination therapies amid global demand surges; it also formed a strategic partnership with Cipla Ltd for co-marketing select products in India and completed a INR 500 crore qualified institutional placement (QIP) funding round in early 2025 to support capacity expansion and R&D investments.